Weight Management Protocol
CagrilintideComplete dosing & administration guide
Long-acting amylin analog that supercharges satiety signals, delivering powerful appetite suppression and up to 10-15% weight loss with convenient once-weekly dosing.
Written & reviewed by Michael Carroll · Research, Peptide Initiative
Dose Range
2.4-2.4mg
Frequency
Once weekly
Route
Subcutaneous injection
Cycle Length
Ongoing/indefinite
Dosing
How much
do I take?
Subcutaneous: A small injection into the fatty layer just under the skin — the same way insulin is given.
Bioavailability High — most of the dose reaches your bloodstream, just more gradually than an IV.
Starting Dose
0.3 mg
In the phase 2 weight study, dosing started low at 0.3 mg weekly and was raised every 2 weeks to reduce nausea [1].
Standard Dose
2.4 mg
A solid mid-range maintenance dose from the dose-finding trial that produced meaningful weight loss [1].
Timing
Best time to take
Same day each week, any time of day that works for your schedule
With food?
Can be taken with or without food - choose whatever is most convenient
If stacking
When combining with semaglutide (CagriSema), both can be injected on the same day. The combination is designed to be taken together for synergistic effects.
Adjusting Your Dose
Increase if
- +You have tolerated the current dose well for at least 4 weeks
- +Weight loss has slowed or plateaued
- +Appetite suppression effects have diminished
- +You want enhanced results and can handle potential increased side effects
Decrease if
- -Experiencing persistent nausea that affects quality of life
- -GI side effects are severe or not improving after 2 weeks
- -Rapid weight loss exceeding 2-3 lbs per week
- -Feeling excessively full or unable to eat adequate nutrition
Signs of right dose
- ✓Gradual, steady weight loss of 1-2 lbs per week
- ✓Noticeably reduced appetite without severe nausea
- ✓Feeling satisfied with smaller portions
- ✓Manageable or no side effects
Dosing Calculator
Calculate Your Exact Dose
Step 1: Peptide Weight
Find the weight printed on your peptide vial label
Look here!
The peptide weight is printed on the label
Look here!
The weight is on the label
Select Weight
Look for a number followed by 'mg' on the vial label (e.g., 5mg, 10mg)
Administration
How do I
use it?
Reconstitution
What you need
- •Bacteriostatic water (BAC water)
- •Insulin syringe (29-31 gauge, 0.5-1mL)
- •Alcohol swabs
- •Sterile vial of cagrilintide powder
- •Sharps container for safe needle disposal
Injection
Route
Subcutaneous injection once weekly
Best sites
- •Abdomen (2 inches away from navel)
- •Front of thigh (middle third)
- •Upper arm (outer area)
- •Lower back area (above buttocks)
Technique
- 1.Wash hands thoroughly and clean injection site with alcohol swab
- 2.Let the alcohol dry completely - this reduces stinging
- 3.Pinch the skin to create a fold for easier injection
- 4.Insert needle at a 45-90 degree angle depending on body composition
- 5.Inject the medication slowly over 5-10 seconds
- 6.Hold for 10 seconds before removing needle, then release skin
Storage
Signs of degradation
Sample Daily Schedule
Safety
Is it
safe?
Safety Profile
Cagrilintide has been studied in multiple Phase 2 and Phase 3 trials involving thousands of participants. The safety profile is generally favorable, with most side effects being GI-related (nausea, constipation, diarrhea) that improve with time and gradual dose escalation. Serious adverse events are rare, and the drug was well-tolerated even at the highest studied doses.
Phase 2 trials included over 700 participants with follow-up periods up to 26 weeks. Phase 3 REDEFINE trials enrolled over 3,400 participants with 68-week follow-up. The combination with semaglutide (CagriSema) showed similar tolerability to semaglutide alone.
Common Side Effects
Experienced by some users
Nausea
The most frequently reported side effect, affecting 20-47% of users depending on dose. Usually mild and improves over the first few weeks.
Management: Start with lower doses and titrate slowly. Eat smaller, more frequent meals. Avoid greasy or heavy foods.
Constipation
Occurs due to slowed gastric emptying and reduced food intake. Reported in 15-25% of users.
Management: Increase fiber and water intake. Stay physically active. Consider a stool softener if needed.
Diarrhea
May occur especially during dose adjustments. Usually temporary and mild to moderate.
Management: Stay well hydrated. Avoid foods that trigger symptoms. Usually resolves within 1-2 weeks.
Injection site reactions
Mild redness, swelling, or itching at injection sites. Generally resolves quickly.
Management: Rotate injection sites regularly. Ensure proper injection technique. Apply ice if needed.
Less Common
- •Vomiting
- •Headache
These typically resolve with continued use or dose adjustment.
Stop and Seek Help If
- ×Severe allergic reaction (rash, swelling, difficulty breathing)
- ×Persistent severe nausea or vomiting not improving with dose reduction
- ×Signs of pancreatitis (severe abdominal pain radiating to back)
- ×Planned pregnancy or positive pregnancy test
- ×Inability to maintain adequate nutrition despite dose adjustments
- ×Any concerning symptoms your healthcare provider advises stopping for
Always consult your healthcare provider before stopping or modifying your dose. Do not stop abruptly without medical guidance, especially if you are also on diabetes medications.
Interactions
With other peptides
- ✓Semaglutide - Designed to be combined - the CagriSema combination shows enhanced weight loss through complementary mechanisms
- ✓Tirzepatide - May be combined, but both affect appetite strongly - monitor for excessive appetite suppression
- ✓BPC-157 - Generally safe to combine for gut support during weight loss
- !Pramlintide - Do NOT combine - both are amylin analogs with overlapping mechanisms
With medications
- !Insulin - Increases hypoglycemia risk - insulin dose may need reduction, especially post-meal doses
- !Sulfonylureas - Increased hypoglycemia risk - may need dose adjustment with provider guidance
- ✓Metformin - Generally safe to combine - may provide complementary metabolic benefits
- ✓Oral medications - Slowed gastric emptying may affect absorption timing - take critical meds separately
With supplements
- ✓Protein supplements - Highly recommended to maintain muscle mass during weight loss
- ✓Fiber supplements - Can help with constipation - take with plenty of water
- ✓Multivitamins - Recommended as reduced food intake may limit nutrient intake
- ✓Electrolytes - Helpful if experiencing GI side effects to prevent dehydration
Published Research
What the studies show
Lau DCW et al. · 2021
Phase 2 trial showed cagrilintide at 4.5mg achieved 10.8% weight loss versus 3% with placebo over 26 weeks in 706 participants. The drug outperformed liraglutide 3.0mg (9.0% weight loss).
Enebo LB et al. · 2021
Phase 1b trial demonstrated that combining cagrilintide with semaglutide 2.4mg resulted in up to 17.1% weight loss at 20 weeks, with the combination being well-tolerated.
Garvey WT et al. · 2025
The REDEFINE 1 Phase 3 trial showed CagriSema achieved 20.4% weight loss versus 3% with placebo over 68 weeks in 3,417 participants. Over half of participants lost 20% or more of body weight.
Kruse T et al. · 2021
Describes the medicinal chemistry development of cagrilintide, explaining how lipidation extended the half-life from minutes (pramlintide) to approximately one week while maintaining receptor activity.
Frias JP et al. · 2023
In people with type 2 diabetes, CagriSema achieved 15.6% weight loss versus 5.1% with semaglutide alone over 32 weeks, with comparable HbA1c reductions and good tolerability.
Head to Head
Cagrilintide compared
Want the Full Picture?
View the complete Cagrilintide research profile including mechanism of action, clinical studies, effectiveness timeline, and FAQ.